Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03YMA
|
|||
| Drug Name |
Aryl pyrimidine derivative 1
|
|||
| Synonyms |
PMID26161698-Compound-43
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
INGENIUM PHARMACEUTICALS GMBH ALLGEIER, HANS AUGUSTIN, MARTIN MUELLER, ANKE ZEITLMANN, LUTZ MARQUARDT, ANDREAS PLEISS, MICHAEL A. HEISER, ULRICH NIESTROJ, ANDR JOHANNES
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H20N4O2
|
|||
| Canonical SMILES |
COC1=CC=CC=C1C2=CC(=NC=N2)NC(=O)C3CCCNC3
|
|||
| InChI |
1S/C17H20N4O2/c1-23-15-7-3-2-6-13(15)14-9-16(20-11-19-14)21-17(22)12-5-4-8-18-10-12/h2-3,6-7,9,11-12,18H,4-5,8,10H2,1H3,(H,19,20,21,22)
|
|||
| InChIKey |
HWNURWPCYJPMQP-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclin-dependent kinase 9 (CDK9) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Cyclin-dependent kinase 9 (CDK9) | Target's Patent Info | [1] | |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Reactome | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||
| WikiPathways | Cardiac Hypertrophic Response | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Host Interactions of HIV factors | ||||
| HIV Life Cycle | ||||
| IL-9 Signaling Pathway | ||||
| RNA Polymerase II Transcription | ||||
| MicroRNAs in cardiomyocyte hypertrophy | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.